BOBULSKY SUSAN sold $115K of ADPT

BOBULSKY SUSAN (Chief Commercial Officer, MRD) sold 5,000 shares of Adaptive Biotechnologies Corp (ADPT) at $23.00 ($0.12M total) on 2026-07-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · BOBULSKY SUSAN
Published Jul 20, 2026, 11:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 20, 2026, 11:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ADPT
Neutral
medium confidence
Mentioned
$ADPT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ADPTNeutralLow
01

Why it matters

The newest fact is the specific sale size, price, and that it was executed under a pre-arranged Rule 10b5-1 plan.

02

Market read

Traders may treat this as routine insider activity with limited fundamental implications, but it can be used for sentiment and positioning checks.

03

What to watch

The article does not state whether the sale was part of a larger series, nor does it provide options activity or other insider buys that could offset the signal.

Relevance 3/10Novelty 4/10Timing: Filed 2026-07-20, disclosing a sale executed 2026-07-16.

Background

The article is an SEC Form 4 insider transaction disclosure for Adaptive Biotechnologies (ADPT).

Company-level read

Ticker impact

$ADPTNeutralMedium confidence
Context

Adaptive Biotechnologies CCO Susan Bobulsky sold 5,000 shares at $23.00 on 2026-07-16 under a 10b5-1 plan, per Form 4.

Expected impact

Low likelihood of a sustained price move; any impact is likely short-lived and sentiment-driven.

Evidence & confidence

The filing is an SEC Form 4 insider transaction with a stated pre-arranged 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.

Market effects

Minimal, as the disclosure is company-specific and not a sector-wide regulatory or clinical catalyst.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with management’s view of near-term risk or valuation, so traders may still watch for follow-on sales.

Key entities

  • Adaptive Biotechnologies Corp

    Company whose insider transaction is disclosed on Form 4.

  • Susan Bobulsky

    Chief Commercial Officer, MRD, who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ADPTHigh

Adaptive (ADPT) Q3 2026 Earnings Call Transcript

Adaptive (ADPT) raised its 2026 MRD revenue guidance due to strong clinical volumes and pharma revenue. Q3 saw 46% YOY growth in clinical testing volume, with 41% growth in clinical revenue. The company earned a milestone payment from Pfizer and is advancing its immune medicine separation process. Blood-based testing and community adoption of clonoSEQ increased significantly. U.S. ASP was $1,380 in Q3, with coverage gains in DLBCL and MCL.

$ADPTHigh

Adaptive Biotechnologies Corp (ADPT) Q3 2026 Earnings Call Highlights: First Profitable

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. US ASP was $1,380, flat sequentially. The company expects no GAAP net income for Q4 or the full year. Challenges include Medicare payment structures and CMS rate uncertainties. Management remains confident in long-term pricing strategy and growth, citing favorable guidelines and market expansion.

$ADPTMedAI 8/10

Adaptive Biotechnologies Q3 Earnings Call Highlights

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. The company raised its full-year MRD revenue outlook to $276M-$286M. Clinical testing volume increased 46% YoY, and clonoSEQ tests grew 10% sequentially. Adaptive expects 42% clinical volume growth for the year and is pursuing Medicare reimbursement updates.